依曲西莫德治疗溃疡性结肠炎患者的内镜、组织学及复合终点
该研究为ELEVATE UC项目的事后分析,评估依曲西莫德在中重度活动性溃疡性结肠炎患者中按组织学和复合终点(组织学/内镜/症状)的疗效及其预后价值。患者按2:1随机接受每日一次口服依曲西莫德2 mg或安慰剂。结果显示依曲西莫德在组织学和复合终点上优于安慰剂,第12周的组织学和内镜改善与第52周临床缓解及内镜改善-组织学缓解相关。
要点
- 依曲西莫德在第12周和第52周的组织学/复合结局(包括内镜改善-组织学缓解和疾病清除)上较安慰剂有显著改善。
- 第12周达到疾病清除者第52周临床缓解比例高于未达到者(73.9% [17/23] vs 28.3% [71/251])。
- 第12周组织学改善与第52周临床缓解相关(OR 2.37,95%CI 1.27-4.41),内镜改善与之强相关(OR 6.36,95%CI 3.47-11.64)。
核心结论
- 依曲西莫德在达到严格的组织学和复合终点方面优于安慰剂。
研究设计与样本
- ELEVATE UC项目的事后分析,中重度活动性溃疡性结肠炎患者按2:1随机接受每日一次口服依曲西莫德2 mg或安慰剂。
- 在第12周(ELEVATE UC 52和ELEVATE UC 12)和第52周(ELEVATE UC 52)评估组织学和复合终点,包括疾病清除(内镜/组织学/症状缓解)。
- 采用逻辑回归分析基线和第12周组织学/复合终点与第52周结局的关联。
主要发现
- 第12周和第52周,依曲西莫德在组织学/复合结局(包括内镜改善-组织学缓解和疾病清除)上较安慰剂有显著改善。
- 第12周达到疾病清除者第52周临床缓解比例为73.9%(17/23),未达到者为28.3%(71/251)。
- 第12周组织学改善与第52周临床缓解相关(OR 2.37,95%CI 1.27-4.41),内镜改善与之强相关(OR 6.36,95%CI 3.47-11.64)。
- 第12周组织学缓解与第52周内镜改善-组织学缓解相关(OR 3.21,95%CI 1.70-6.06),内镜改善与之强相关(OR 5.47,95%CI 2.89-10.36)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Histologic remission, a potentially important treatment target in ulcerative colitis (UC), is associated with favorable long-term outcomes. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC. This post-hoc analysis of the ELEVATE UC program evaluated the efficacy of etrasimod according to histologic and composite (histologic/endoscopic/symptomatic) endpoints and examined their prognostic value. METHODS: Patients with moderately to severely active UC were randomized 2:1 to once-daily oral etrasimod 2 mg or placebo. Histologic and composite endpoints, including disease clearance (endoscopic/histologic/symptomatic remission), were assessed at Weeks 12 (ELEVATE UC 52; ELEVATE UC 12) and 52 (ELEVATE UC 52). Logistic regressions examined associations between baseline and Week 12 histologic/composite endpoints and Week 52 outcomes. RESULTS: At Weeks 12 and 52, significant improvements with etrasimod vs placebo were observed in histologic/composite outcomes, including endoscopic improvement-histologic remission and disease clearance. The proportion of patients treated with etrasimod achieving clinical remission at Week 52 was higher among those with disease clearance at Week 12 vs those without disease clearance (73.9% [17/23] vs 28.3% [71/251]). Histologic improvement and endoscopic improvement at Week 12 were moderately and strongly associated with clinical remission at Week 52 (odds ratio [OR], 2.37; 95% confidence interval [CI], 1.27-4.41; and OR, 6.36; 95% CI, 3.47-11.64, respectively). Histologic remission and endoscopic improvement at Week 12 were strongly associated with endoscopic improvement-histologic remission at Week 52 (OR, 3.21; 95% CI, 1.70-6.06 and OR, 5.47; 95% CI, 2.89-10.36, respectively). CONCLUSIONS: Etrasimod was superior to placebo for achievement of stringent histologic and composite endpoints. CLINICALTRIALS: gov, Number: NCT03945188; ClinicalTrials.gov, Number: NCT03996369.
引用
- Magro F, Peyrin-Biroulet L, Sands BE, et al. Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod. Clin Gastroenterol Hepatol. 2024. PMID: 39089519. doi:10.1016/j.cgh.2024.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。